Merck KGaA Starts Enpatoran Phase 3 for Lupus Skin Flares
Key Questions
What progress has been made with enpatoran for cutaneous lupus?
Phase 2 WILLOW data showed CLASI-A score reductions of 64-72%, and the first patient has been dosed in the Phase 3 ELOWEN-1/2 trials evaluating enpatoran, an oral TLR7/8 inhibitor, for active skin manifestations.
What EULAR 2025 data supports enpatoran and related therapies?
New data confirm enpatoran and ianalumab sustain efficacy with no new safety signals, and ianalumab benefit persists after B-cell recovery. A systematic review also identifies anifrolumab, sifalimumab, deucravacitinib, and BIIB059 as effective targeted CLE therapies.
How do CLE treatment responses vary by subtype?
A Yale study on CLE treatment patterns shows responses to systemic therapies differ by CLE subtype in patients with concomitant SLE, while litifilimab has demonstrated CLE improvement at 24 weeks in recent EULAR 2026 data.
Ph2 WILLOW shows CLASI-A drops 64-72%; first patient dosed in enpatoran Phase 3 ELOWEN-1/2 for active skin manifestations (oral TLR7/8 inhibitor). New EULAR 2025 data shows enpatoran and ianalumab (BAFF-R inhibitor) sustain efficacy with no new safety signals; ianalumab benefit persists after B-cell recovery. Broader cutaneous lupus pipeline expanding, including new EULAR 2026 data for litifilimab improving CLE at 24 weeks. A systematic review confirms anifrolumab, sifalimumab, deucravacitinib, and BIIB059 as effective targeted therapies for CLE, while RSLV-132 and epratuzumab failed. A TLR7/8 fact sheet from BMS provides educational context. A new Yale study on CLE treatment patterns shows responses to systemic therapies vary by CLE subtype in patients with concomitant SLE, adding nuance to management.